Anxious-depressive disorders and metabolic syndrome

Czech version

Authors: H. Rosolová ^1,2; J. Podlipný ³
Authors‘ workplace: Centrum preventivní kardiologie II. interní kliniky Lékařské fakulty UK a FN v Plzni, přednosta prof. MUDr. Jan Filipovský, CSc. ¹; Český Institut metabolického syndromu, o. p. s. ²; Psychiatrická klinika Lékařské fakulty UK a FN v Plzni, přednosta doc. MUDr. Jiří Beran, CSc. ³
Published in: Vnitř Lék 2009; 55(7-8): 650-652
Category: 134th Internal Medicine Day - 23rd Vanysek's Day Brno 2009 - Vanysek's Lecture

Overview

Anxiety and depressive behavioural disorders often occur concomitantly and their incidence in the general population as well as in chronically ill is higher than anticipated. Pilsen study of male and female patients (N = 1,050) selected from a population-based sample of the primary prevention survey PILS III (Pilsen Longitudinal Study III) had proven an existence of associations between depressive behavioural disorder and metabolic syndrome (MS). Depressive disorders were nearly twice as frequent in patients with MS compared to individuals without MS (RR = 1.85; CI: 1.11–3.10). Patients with psychiatric disorders were excreting more cortisol in the urine than individuals without psychiatric disorders, while there was no difference in the excretion of catecholamines and serotonin. Our results provide an indirect evidence for the hypothesis suggesting that increased activation of the sympathoadrenal axis could be pathophysiologically involved in the concomitant occurrence of the typical MS risk factors and depressed mood. Anxiety and depressive disorders are linked to higher cardiometabolic risk, higher incidence of acute cardiovascular events as well as poorer prognosis for cardiac patients; they are co-morbid to a range of other chronic internal diseases. The association between cardiovascular disease, diabetes and psychiatric disorders is bilateral, i.e. patients with anxiety and depression experience cardiovascular events more frequently, and the patients with type 2 diabetes and cardiometabolic diseases suffer more frequently from anxious-depressive disorder. In clinical practice, we should search for anxious-depressive disorders. At present, the patients with anxiety or depression should be considered in the primary disease prevention as patients at high risk of atherosclerotic vascular diseases as well as MS and type 2 diabetes. Treatment of these diseases as part of secondary prevention in patients with anxiety and depression must be more rigorous and intensive than in patients without these psychiatric disorders.

Key words:
metabolic syndrome – anxiety – depressive disorder – atherosclerotic vascular diseases – type 2 diabetes mellitus

Sources

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

2. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

3. Thomas AJ, Kalaria RN, O’Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord 2004; 79: 81–95.

4. Wassertheil-Smoller S, Shumaker S, Ockene J et al. Depression and cardiovascular sequelae in postmenopausal women. The Women’s Health Initiative (WHI). Arch Intern Med 2004; 164: 289–298.

5. Petrlová B, Rosolová H, Hess Z et al. Depressive disorders and the metabolic syndrome of insulin resistance. Semin Vasc Med 2004; 4: 161–165.

6. Larkin KT. Stress and Hypertension. Examining the relation between psychological stress and high blood pressure. New Haven: Yale University Press 2005.

7. Seematter G, Binnert C, Tappy L. Stress and metabolism. Metab Syndr Relat Disord 2005; 3: 8–13.

8. Podlipný J a kol. Deprese a civilizační choroby. Praha: Maxdorf 2007.